BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22692499)

  • 1. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
    van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
    Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.
    van Til NP; Sarwari R; Visser TP; Hauer J; Lagresle-Peyrou C; van der Velden G; Malshetty V; Cortes P; Jollet A; Danos O; Cassani B; Zhang F; Thrasher AJ; Fontana E; Poliani PL; Cavazzana M; Verstegen MM; Villa A; Wagemaker G
    J Allergy Clin Immunol; 2014 Apr; 133(4):1116-23. PubMed ID: 24332219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer.
    Pike-Overzet K; Rodijk M; Ng YY; Baert MR; Lagresle-Peyrou C; Schambach A; Zhang F; Hoeben RC; Hacein-Bey-Abina S; Lankester AC; Bredius RG; Driessen GJ; Thrasher AJ; Baum C; Cavazzana-Calvo M; van Dongen JJ; Staal FJ
    Leukemia; 2011 Sep; 25(9):1471-83. PubMed ID: 21617701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.
    Zhang F; Thornhill SI; Howe SJ; Ulaganathan M; Schambach A; Sinclair J; Kinnon C; Gaspar HB; Antoniou M; Thrasher AJ
    Blood; 2007 Sep; 110(5):1448-57. PubMed ID: 17456723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
    Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
    Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.
    Punwani D; Kawahara M; Yu J; Sanford U; Roy S; Patel K; Carbonaro DA; Karlen AD; Khan S; Cornetta K; Rothe M; Schambach A; Kohn DB; Malech HL; McIvor RS; Puck JM; Cowan MJ
    Hum Gene Ther; 2017 Jan; 28(1):112-124. PubMed ID: 27611239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells.
    Benjelloun F; Garrigue A; Demerens-de Chappedelaine C; Soulas-Sprauel P; Malassis-Séris M; Stockholm D; Hauer J; Blondeau J; Rivière J; Lim A; Le Lorc'h M; Romana S; Brousse N; Pâques F; Galy A; Charneau P; Fischer A; de Villartay JP; Cavazzana-Calvo M
    Mol Ther; 2008 Aug; 16(8):1490-9. PubMed ID: 18560421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.
    Capo V; Castiello MC; Fontana E; Penna S; Bosticardo M; Draghici E; Poliani LP; Sergi Sergi L; Rigoni R; Cassani B; Zanussi M; Carrera P; Uva P; Dobbs K; Sacchetti N; Notarangelo LD; van Til NP; Wagemaker G; Villa A
    J Allergy Clin Immunol; 2018 Sep; 142(3):928-941.e8. PubMed ID: 29241731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
    Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
    Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector.
    Dighe N; Khoury M; Mattar C; Chong M; Choolani M; Chen J; Antoniou MN; Chan JK
    PLoS One; 2014; 9(8):e104805. PubMed ID: 25118036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors.
    Taher TE; Tulone C; Fatah R; D'Acquisto F; Gould DJ; Mageed RA
    Gene Ther; 2008 Jul; 15(13):998-1006. PubMed ID: 18356817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter.
    Demaison C; Parsley K; Brouns G; Scherr M; Battmer K; Kinnon C; Grez M; Thrasher AJ
    Hum Gene Ther; 2002 May; 13(7):803-13. PubMed ID: 11975847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression.
    Di WL; Semenova E; Larcher F; Del Rio M; Harper JI; Thrasher AJ; Qasim W
    Hum Gene Ther; 2012 Jan; 23(1):83-90. PubMed ID: 21895535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral MGMT(P140K)-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter.
    Phaltane R; Lachmann N; Brennig S; Ackermann M; Modlich U; Moritz T
    Biomaterials; 2014 Aug; 35(25):7204-13. PubMed ID: 24875758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells.
    Cui Y; Golob J; Kelleher E; Ye Z; Pardoll D; Cheng L
    Blood; 2002 Jan; 99(2):399-408. PubMed ID: 11781219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for PIDs: progress, pitfalls and prospects.
    Mukherjee S; Thrasher AJ
    Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
    Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
    Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
    Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
    Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.